Item 2.02. Results of Operations and Financial Condition.

On January 11, 2021, EyePoint Pharmaceuticals, Inc. (the "Company") issued a press release announcing its preliminary fourth quarter and full-year 2020 revenues, and certain other corporate updates. The amounts included in the press release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2020. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2020. A copy of the press release is filed as Exhibit 99.1 hereto.

The information included under Item 2.02 of this current report on Form 8-K, including Exhibit 99.1, is deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and, therefore, may be incorporated by reference in filings under the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.                                   Description
99.1            Press Release of EyePoint Pharmaceuticals, Inc., dated January 11, 2021
104           Cover Page Interactive Data File (embedded within the inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses